Institutional Fund
Omega Fund Management, LLC
Boston, MACIK 16373596 filings on record
Portfolio Value
$163.15M
Q1 2026
Holdings
10
Reported positions
New Buys
0
Opened this quarter
QoQ Change
-43.1%
from $286.52M
Portfolio Value Trend
Reported 13F value by quarter
Portfolio value trend — upgrade to see history
UpgradeTop Allocations
Largest positions by weight
- Bicara Therapeutics Inc29.2%
- Nuvation Bio Inc21.2%
- Bridgebio Oncology Therapeut18.0%
- Kestra Med Technologies Ltd12.5%
- Beta Bionics Inc8.1%
- Engene Holdings Inc3.7%
- Other7.3%
Portfolio Holdings
10 positions · Q1 2026
| # | Security | Shares | Value | % Port. | Δ Shares | Activity |
|---|---|---|---|---|---|---|
| 1 | Bicara Therapeutics Inc | 2.39M | $47.58M | 29.2% | +187.5K | Added |
| 2 | Nuvation Bio Inc | 8.08M | $34.67M | 21.2% | 0 | Held |
| 3 | Bridgebio Oncology Therapeut | 3.29M | $29.44M | 18.0% | 0 | Held |
| 4 | Kestra Med Technologies Ltd | 1.02M | $20.37M | 12.5% | −351.4K | Reduced |
| 5 | Beta Bionics Inc | 1.32M | $13.19M | 8.1% | 0 | Held |
| 6 | Engene Holdings Inc | 876.4K | $5.97M | 3.7% | 0 | Held |
| 7 | Alumis Inc | 241.3K | $5.31M | 3.3% | −412.0K | Reduced |
| 8 | Sana Biotechnology Inc | 843.8K | $2.43M | 1.5% | 0 | Held |
| 9 | Imagenebio Inc | 455.4K | $2.28M | 1.4% | 0 | Held |
| 10 | Replimune Group Inc | 248.7K | $1.91M | 1.2% | 0 | Held |